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Background. While human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes preferentially target
specific regions of the viral proteome, HIV-1 features that contribute to immune recognition are not well understood. One
hypothesis is that similarities between HIV and human proteins influence the host immune response, i.e., resemblance
between viral and host peptides could preclude reactivity against certain HIV epitopes. Methodology/Principal Findings. We
analyzed the extent of similarity between HIV-1 and the human proteome. Proteins from the HIV-1 B consensus sequence from
2001 were dissected into overlapping k-mers, which were then probed against a non-redundant database of the human
proteome in order to identify segments of high similarity. We tested the relationship between HIV-1 similarity to host encoded
peptides and immune recognition in HIV-infected individuals, and found that HIV immunogenicity could be partially
modulated by the sequence similarity to the host proteome. ELISpot responses to peptides spanning the entire viral proteome
evaluated in 314 individuals showed a trend indicating an inverse relationship between the similarity to the host proteome
and the frequency of recognition. In addition, analysis of responses by a group of 30 HIV-infected individuals against 944
overlapping peptides representing a broad range of individual HIV-1B Nef variants, affirmed that the degree of similarity to the
host was significantly lower for peptides with reactive epitopes than for those that were not recognized. Conclusions/
Significance. Our results suggest that antigenic motifs that are scarcely represented in human proteins might represent more
immunogenic CTL targets not selected against in the host. This observation could provide guidance in the design of more
effective HIV immunogens, as sequences devoid of host-like features might afford superior immune reactivity.
Citation: Rolland M, Nickle DC, Deng W, Frahm N, Brander C, et al (2007) Recognition of HIV-1 Peptides by Host CTL Is Related to HIV-1 Similarity to
Human Proteins. PLoS ONE 2(9): e823. doi:10.1371/journal.pone.0000823
INTRODUCTION
HIV-1-specific CD8+ T cell responses play a pivotal role in
controlling HIV-1 replication, despite being rarely if ever able to
fully contain viral replication in vivo. The protective role of CD8+
T cells against disease progression is strongly suggested by studies
in HIV-infected individuals [1–3] and by T cell depletion studies
in SIV-infected rhesus macaques [4–6]. However, definition of the
specificity and functional characteristics of the CD8+ T cell-
mediated immunity required for effective viral control has proven
elusive.
Considering the high number of potential epitopes, anti-HIV
CTL responses tend to target a relatively limited set of epitopes in
a distinct hierarchical pattern [7], with some epitopes engendering
strong responses (immunodominant), weak to barely detectable
responses (subdominant) and even some that are only detectable in
the absence of dominant epitopes (cryptic). Immunodominance in
the antiviral response results from a combination of factors that
include: the efficiency of antigen processing and presentation, the
stability of peptide-MHC complexes, the overall number of peptide-
MHC complexes, the available TCR repertoire, the competition
between CD8+ clones for activation, viral evolution, or/and the
concept of immunodomination in which T cells specific for some
peptidessuppressresponsestootherepitopes[7–11].Thehierarchies
ofT cell responses elicited byHIV infection are generally stable, e.g.,
specific HIV regions are consistently targeted across diverse ethnic
groupsdespitetheirdifferentHLAdistributionsanddistinctinfecting
subtypes [12]. Although some dominant response patterns may be
due to degrees of sequence conservation, recent analyses show that
subdominant responses outside of highly conserved protein regions
cansignificantlycontributetothe invivocontrol[13,14].Althoughno
consistent correlation has been found between breadth of CTL
responses and long-term viral control, it might prove advantageous
for HIV-1 vaccines to overcome the immunodominance pattern seen
in natural infection. Thus, detailed understandingof mechanismsthat
dictate HIV (non)-immunogenicity could help to induce alternative
combinations of more evenly distributed immune responses as
a means to optimize CTL responses in the vaccination setting.
As it is vital for the immune system to tolerate autologous
structures for its proper regulation, any model of immunodomi-
nance should consider the potential impact of self/non-self
discrimination. A breakdown in self-tolerance can lead to the
onset of autoimmune diseases. It was proposed that self-tolerance
might be infringed in autoimmunity by the activation of T cells
directed against cryptic self-determinants [15,16]: well-processed
and -presented antigenic determinants are immunodominant,
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specific T cells and are thus cryptic. Then, certain conditions (e.g.,
addition of a cleavage site [17] or of inflammatory mediators [18])
can help circumvent self tolerance and thereby lead to auto-
immunity. Viral or bacterial infections have also been suspected as
triggering factors for autoimmune disorders, possibly through
molecular mimicry and/or bystander activation of autoreactive
cells. Indeed, as early as 1986, viral mimicry was suggested to play
a role in the immune dysregulation seen in HIV infection, on the
basis of i) HIV-1’s structural similarities with MHC and various
immune regulatory molecules [19–23] and ii) the presence of
autoantibodies to HLA molecules [24–26].
We hypothesize that dominance profiles in the HIV-specific
CTL responses reflect an inverse relationship between the
similarity of an HIV epitope to the host proteome and its
immunogenicity. The underlying rationale is that the immune
system preferentially responds to antigenic sequences that are
never or only sporadically encountered in the repertoire of self-
antigens. To better understand the reported dominance patterns
among responses to HIV-1 antigens, we first analyzed the extent of
similarity between HIV-1 and the human proteome. Then, we
present the first comprehensive investigation of the relationship
between similarity to host and the profile of immune responses
elicited against the whole HIV proteome in 314 HIV-infected
individuals and against 944 overlapping peptides representing
a broad range of individual HIV-1B Nef variants in 30 individuals.
In doing so, we validated our hypothesis that HIV immunogenic-
ity could be partially regulated by similarities to the host proteome.
RESULTS
‘‘Human-like’’ motifs in the HIV-1 proteome
We first identified HIV-1 segments with sequence identity (4-, 5-
and 6-mers) or high similarity (9-mers) to human proteins by
comparing all possible 4, 5, 6 or 9-mers derived from HIV-1 B
consensus 2001 to the human proteome. Sequential overlapping k-
mers were scanned using BLASTP [27–29] against a non-
redundant library of human proteins to identify exact matches
for 4, 5 and 6-mers while allowing up to 2 mismatches for 9-mers,
since cross-reactivity drops markedly beyond 2 changes out of 9
amino acids (AA) (Heckerman, unpublished data).
Besides previously described similarities with MHC molecules
[19–23,30], numerous matches corresponded to human endogenous
retrovirus (HERV) sequences. This was expected since endogenous
retroviruses reflect past exogenous retroviral infections and are
a large (2 to 8%) component of the human genome [31], with 950
full length reverse transcriptase (RT) [32] and 16 candidate genes
potentially encoding functional Envelope (Env) proteins. The
analysis also revealed HIV-1 similarities to proteins previously
described as autoantigens, a conspicuous fact since the repertoire of
autoantigens is thought to be limited to a few hundred [33]. The
number of exact 4-mer HIV-1 matches against a set of 103
autoantigens (77.54 matches/1000AA) was significantly greater than
matches against all proteins (54.56 matches/1000AA) (x
2=9.677).
Segments in all HIV-1 proteins except Tat, Rev, and Vpr showed
high similarities to various proteins of the NACHT-LRR (leucine-
rich repeats) family, which have been implicated in apoptosis,
inflammation and autoimmunity, in particular in the control of
immune and inflammatory responses, and include key regulators of
pathogen recognition [34]. Though their exact roles are not clearly
defined, some NACHT-LRR have been genetically linked to
immunological disorders [35], including immunodeficiency [36].
We next focused our search on nonamers, the typical length of
epitopes presented by HLA class I molecules, in order to identify
the longest ‘‘human-like’’ motifs. We identified 16 HIV oligomers
considered similar to human proteins since they differed by 3
standard deviations from the similarity expected with randomized
nonamers (Table 1). Of note, the HIV-1 consensus sequence
showed only 2 mismatches with the 37-AA-long protein RAK
[37]. However, based on virtual identity over 142 nucleotides to
an HIV-1 isolate and lack of adaptation to human genome codon
usage, the reportedly cancer-associated protein RAK is most likely
an HIV contaminant (Learn, unpublished data). To account for
HIV-1’s extensive variability, the remaining 15 oligomers were
compared to the full spectrum of HIV-1 sequences available in
databases in order to identify further similarities. Briefly, the
shared segments extended to one identical nonamer (in the protein
Copine 5) and up to 11 identical AA out of 13 (RT of an HERV-K
sequence).
Finally, a spectrum of 182 HIV-1 B Env sequences dating from
1983 to 2005 was scanned for similarities to human proteins in
order to identify whether HIV was adapting to become more or
less host-like over time. Despite marked differences among
individual HIV-1 sequences, there was no evidence of change in
the degree of similarity to host proteins since the beginning of the
widespread epidemic (data not shown).
Inverse relationship between similarity of HIV to its
host and its immunogenicity
To investigate whether the similarity of HIV to its host participates
in shaping the antiviral CD8+ T cell responses, we compared the
similarity to human proteins of 410 HIV-1 peptides spanning the
whole viral proteome to their frequency of recognition measured
by IFN-c ELISpot assays in 314 HIV-infected individuals [12]. We
found a trend indicating an inverse relationship between the
similarity to the host proteome and the ELISpot reactivity
(Figure 1), consistent with our hypothesis that antigenic motifs
scarcely represented in human proteins are more likely to be CTL
targets for the host. The peptides that most frequently elicited
a response presented less matches to human proteins, i.e., a low
similarity to the host. Conversely, the peptides with high number
of matches to human proteins more rarely elicited CTL responses.
Numerous peptides were never or only marginally recognized in
the population; hence our observation is only supported by a trend
(r
2=0.0096). Nonetheless, when Figure 1 is divided in 4 quadrants
(based on the mean plus one standard deviation for the normalized
similarity to the human proteome (x axis) and for the frequency of
recognition by ELISpot (y axis)), the paucity of peptides in the top
right quadrant (2 data points out of 410) emphasized that peptides
with a high similarity to the host usually elicited CTL responses
only in a small proportion of HIV-1 infected individuals. We
randomized the relationship between the x and y axes and counted
the number of times that both x and y axis values were superior to
the mean plus one standard deviation (i.e., would fall in the top
right quadrant). 1,000 randomizations were performed and there
were 46 occurrences with no more than 2 data points meeting the
criteria; hence, the dearth of data points in the top right quadrant
found in our data would not be expected by chance (p=0.046)
and thus supported the hypothesis that peptides with high
similarity to host proteins had a lower propensity to be recognized
by the host CTL.
To lift the uncertainty in epitope specificity cast by using 18-mer
peptides, 944 10mer peptides encompassing Nef were screened in
30 HIV-infected individuals using IFN-c ELISpot assays. The 944
Nef 10-mers, akin to or slightly larger than the typical size of an
HLA class I epitope, overlapped by 9 residues and represented
a broad array of HIV-1 variants found in the population (Frahm
HIV Mimicry of Human Proteome
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least one patient while 598 did not. Peptides that were recognized
had a significantly lower degree of similarity to human proteins
than the 10-mers that were not reactive. Considering 9-mer
matches (allowing 2 mismatches), the mean number of matches
was 1.40 for the peptides eliciting a response compared to 3.16 for
those that do not elicit any response (p=0.0002). Similarly, for
5- and 6-mer exact matches, the mean number of matches were
55.75 and 3.09, respectively, for the peptides eliciting a response,
compared to 107.51 and 6.02, respectively, for those that failed to
elicit any response (p=0.0002 and ,0.0001, respectively). Since
the peptides are overlapping, we did a cross-validation analysis to
verify that overweighting the degree of similarity to humans or re-
counting responses did not skew our results. We partitioned our
data in 10 non-overlapping sets of peptides (each including from
88 to 102 peptides) and compared the similarity to human proteins
to the ELISpot reactivity for each set. Although the p-values were
affected (11 out of 30 were .0.10), ELISpot reactive peptides
showed less similarity to human proteins than non-reactive ones.
Last, we analyzed the magnitude of ELISpot responses elicited
by the Nef peptides stratified according to their similarity to their
closest human peptides. The mean magnitudes (number of spot-
forming cells) of the ELISpot responses were higher when the Nef
peptides were more distant from their closest human peptides.
When the Nef peptides had, respectively, 1, 2, 3 or 4 mismatches
with their closest human peptides, the mean magnitudes were 0,
220.00, 237.99 and 654.18 respectively (Spearman correlation
factor rho=0.1911 and p-value=3.2622e-09) (Figure 2).
Multiple factors influence HIV-1 immunogenicity
The hypothesis of immunodominance being related to low
similarity to self is beguiling but there are undoubtedly other
concurring factors. Frahm et al. (2004) previously analyzed
different parameters affecting a peptide’s ability to elicit an
immune response. ELISpot reactivity was favored by low peptide
variability, low representation of forbidden AA (i.e., AA not
generally found at the C-terminus of CD8+ T cell epitopes) and
high proteasome cleavage likelihood scores. In addition, HIV
regions enriched in CTL epitopes were shown to be more
hydrophobic [38,39]. In our genome-wide analysis, the relation-
ship between peptide hydrophobicity and frequency of recognition
was strongly supported only for Gag and Nef (data not shown).
Overall, the effects of entropy and of forbidden residues were
more pronounced than those of the degree of similarity to self,
hydrophobicity, or disorder prediction score, as shown by
a multivariate analysis: Y=9.41, 20.38 (similarity), 25.22
(forbidden AA), +0.03 (hydrophobicity), 20.11 (disorder), 25.75
(entropy). In addition, it is important to note that the ratio of
forbidden AA at the C-terminus of CD8+ T cell epitopes and the
similarity to host proteins are positively correlated (p=0.026):
peptides highly similar to host proteins are not frequently
Table 1. HIV-1 nonamers with high similarities to human proteins.
..................................................................................................................................................
Significant 9-mers
consensus 2001
Human Protein
sequence Human protein
HIV database seq.
corresponding to
human prot. seq.
HIV-I B consensus
2001 position
Identities
(Positives)
LHPVHAGPI LnPVHAGPIV PTPRE Gag 215–223 9/10 (10/10)
LHPGHAEPIV T cell leukemia Homeobox 1 LHPVHAEPI 8/10
EPFRDYVDRF VPFRDYVDR COPINE 5 AAV71076 Gag 291–300 8/9
PFRDYVDRS AAV53244 8/9
PDCKTILKA HPDCKTI DELTEX 4 homolog AAV49378 Gag 328–336 7/7
NTPVFAIKKK SPWNTPVFVIKKK HERV PYNTPVFVIKKK Pol 209–221 11/13
MTKILEPFR MTKILEPC Piwi-like 2 AAM74596 Pol 319–327 7/8
sMTKILDSF SON DNA Binding P. AAK35877 6/9 (7/9)
FKNLKTGKY FKNSKTG Str Spe Recognition P. FKNNKT Pol 501–508 6/7
VNIVTDSQYA VNIYTDSQYA HERV VNIITDSQYA Pol 648–657 9/10
VNTVTDDDYA Thrombospondin 3 precursor VNIVTDsEYA 7/10
YIEAEVIPA GYIEAAVIPAG unnamed P. Pol 798–806 10/11
EIEAEV p53 inducibleP. AAV49469 6/6
NWRSELYKY HNWRSELY peroxysomal acylcoA thioestherase CAA64162 Env 469–477 7/8
AAG…TVW 35/37 Cancer associated RAK Env 516–572 35/37
DQGPQREPY qRP–DQGPQRPP carcinoma ass. P. DQGPQRAP Vpr 7–15 9/13 (10/13)
DQGPQRPP proline rich 7/8
PKTACTNCY SQPKsACGNCY Zn finger P. SQPKtACSNCY Tat 18–26 9/11 (10/11)
LAIVALVVA ALVALVVAPL Trypsin-domain P. ALVALVVAVL Vpu 7–15 9/10
LAIVALAV small inducible cytokine 28 7/8
EELLKTVRL EELLKEVRL nucleolar RNA associated P. EELLKAVRL Rev10–18 8/9
LLKTVRLLRLL LLKTVRLiRLL 10/11
TVRERMRRA TTVRSRMRRA Rhomboid P. Nef 15–23 9/10
IYSQKRQDI TYSQKFQDI Ig heavy chain variable region TYSQKRQDI Nef 101–109 8/9
The level of similarity to host proteins for these HIV nonamers differed by 3 standard deviations from the level of similarity found with randomized nonamers. Amino
acid changes are in bold italics and lower case.
doi:10.1371/journal.pone.0000823.t001
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forbidden AA, i.e., they are expected to be poorly presented.
Lastly, we asked whether disorder/order of the peptides played
a role in HIV immunogenicity. Disordered regions present a low
sequence complexity with many repetitive elements coupled with
a biased amino acid content deprived of bulky hydrophobic amino
acids (that typically form the cores of folded globular proteins)
while they are enriched in alanine, arginine, glycine, glutamine,
serine, proline, glutamate and lysine that results in highly charged
surfaces [40]; they are reported to bind to nucleic acid and form
coiled-coils [41]. Different factors led us to take structural disorder
into account: 1) many HIV segments showed similarity to auto-
antigens, which have a propensity for intrinsic disorder [41], 2) the
presence of disorder in TY transposable element proteins suggests
that it is a feature of retroviruses, since TY elements in the yeast
genome result from retroviral infection [42], and 3) Tat was
recently shown to be unfolded in its native state [43]. We found
that most HIV proteins presented regions of intrinsic disorder and
that highly disordered peptides did not elicit broad CTL responses
while highly recognized peptides showed low peptide disorder
(Figure 3).
DISCUSSION
Our data highlight a likely influence of the similarity to human
sequences in shaping the host’s immune response to HIV-1. We
found that HIV-1 infected individuals seldom recognized the most
‘‘human-like’’ peptides, while the peptides that were frequently
recognized showed a low similarity to the host. The relationship
between HIV-1B similarity to host proteins and its immunoge-
nicity was evidenced in 2 ways by analyzing CTL responses
against i) 410 consensus peptides representing the whole HIV-1 B
proteome in a cohort of 314 individuals and ii) 944 variant Nef
peptides in 30 individuals. Furthermore, the more a Nef peptide
was different from its closest human peptide, the stronger the
immune response it elicited. These results, stemming from
consensus and circulating HIV variants, support HIV’s degree of
similarity to host as a mechanism contributing to the intrinsic
hierarchical profile of HIV-specific CD8+ T cell responses seen
across different cohorts and host ethnicities [12,44–48]. However,
Figure 1. Frequency of recognition of HIV-1 B consensus 2001 peptides as a function of their similarity to human proteins. 410 peptides
spanning the HIV-1 B consensus 2001 proteome were tested by ELISpot using PBMC from a cohort of 314 HIV-1 infected individuals. The vertical axis
corresponds to the percentage of individuals who recognized a given peptide. The horizontal axis corresponds to the number of matches to the
human proteome for each peptide. Matches were derived by dissecting the 410 peptides into overlapping 6-mers offset by one residue, and then
scored against the RefSeq protein sequence database. Matches were normalized to account for the length of the starting peptide (ranging from
15–20 AA in length).
doi:10.1371/journal.pone.0000823.g001
Figure 2. Magnitude of the ELISpot responses elicited by HIV-1 B Nef
peptides as a function of their similarity to human peptides. The
vertical axis corresponds to the mean number of spot-forming cells
counted in ELISpot assays. The horizontal axis corresponds to Nef
peptides that have 2, 3 or 4 differences with their closest human
peptides.
doi:10.1371/journal.pone.0000823.g002
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1 peptides and is unlikely to impact the immune evasion that plays
a critical role in disease progression in HIV infected individuals.
The relationship between HIV peptides’ similarity to self and
immunogenicity is nonetheless worthwhile understanding in the
absence of clear correlates between breadth/magnitude of CTL
responses and viral containment.
Although the extent of similarity between HIV and human
proteins is relatively limited, a variety of segments are shared
between HIV and host proteins, particularly proteins involved in
host immunity, underlining a potential role of HIV-1’s similarity to
host in the interference with effectors of the immune system. For
example, it could be expected that HIV/HERV mimics would
have reduced immunogenicity, as negative selection in the host
should have largely eliminated reactive T cell populations. Indeed,
HERV expression was detected in the thymus, where immune
tolerance toward self is maintained via central tolerance;
thymocytes with a high affinity for self-antigens are deleted, thus
the remaining thymocytes (the future CD4+/CD8+ T cells) are
likely to have a low affinity for HERV-like antigens. It should be
noted that high similarity to HERV was found outside of the
reverse transcriptase active site (where similarities between
enzymes are expected). In addition, frequent similarities between
HIV and autoantigens suggest the possibility of cross-reactive
responses through molecular mimicry. This may help explain why
HIV patients appear to be more prone to develop autoantibodies,
in particular against cardiolipin, ribonucleoproteins, smooth
muscle, platelets or cryoglobulinemia [49–52]. Moreover, two
broadly neutralizing HIV-1 monoclonal antibodies were found to
be autoreactive against the self-protein cardiolipin [53], and
antibodies cross-reacting with HIV-1 p24 are found in 30% of
patients with the autoimmune Sjogren’s syndrome [54]. Although
auto-reactive responses are usually neither harmful nor do they
lead to overt autoimmune diseases in most patients, HIV antigens
depleted of self-mimicking elements may represent safer vaccines.
By showing a relationship between peptide similarity and
immunodominance we validated low similarity to the host
proteome as a concurring factor in the modulation of the pool
of epitopic sequences, with a potential role in discriminating
immunodominant from cryptic peptides. Nonetheless, it must be
added that the molecular basis of immunogenicity is the outcome
of numerous interacting factors, among which we studied
structural disorder. Intrinsically disordered regions are protein
segments which lack a fixed tertiary structure (i.e., they are
partially or fully unfolded); they are involved in many biological
functions including cell signaling, regulation, molecular recogni-
tion and other interactions with proteins and nucleic acids [55].
Thus, the intrinsic disorder of HIV segments, and their associated
conformational flexibility and potentially proteolytic lability could
impact the skewed immune response seen in HIV infection. It is
possible that native disorder could be involved in allowing the
virus to evade immune detection, since disordered regions would
generally correspond to poor activators of B cells, with few B cells
able to bind with high affinity to disordered determinants.
Figure 3. Frequency of recognition of HIV-1 B consensus 2001 peptides as a function of their intrinsic disorder prediction score. The vertical axis
corresponds to the percentage of HIV-1 infected individuals that recognized each of the 410 peptides spanning the HIV-1 B consensus 2001
proteome. The horizontal axis corresponds to the disorder prediction score for each peptide, calculated using predictions of order/disorder made
with the VSL1 predictor (PONDRH).
doi:10.1371/journal.pone.0000823.g003
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impact HIV-specific immune responses, our analysis only addressed
sequence identity and MHC-1 responses, since investigating the
impact of structural similarity between virus and host is currently
hampered by the enormous computing power required and the
limited knowledge of the structural conformation of epitopes.
Since it was recognized that some conformational structures are
favored for HLA binding [56], immunogenicity profiles have been
analyzed with respect to several physico-chemical proprieties,
including hydrophobicity. The presence of HLA binding motifs or
processing signals, together with the absence of AA that negatively
impact peptide cleavage, have been previously associated with the
propensity to elicit a response [38,39]. We found a positive
relationship between the similarity to host proteins and the
proportion of AA that are typically absent from the C-terminus of
CD8+ T cell epitopes. Thus, peptides with a high similarity to self
are expected to be poorly processed and presented, and thereby
are likely to be cryptic determinants. Indeed, our data show that
those peptides are typically marginally targeted in the population.
Moreover, since we identified similarities between HIV and some
autoantigens, we can also envisage that the similarity of HIV
epitopes with host proteins could reverse the cryptic nature of
these self-epitopes and thereby lead to the initiation of auto-
reactivity. Together, our data corroborate and extend the model
proposed by Moudgil and Sercarz, which puts forth the gradient of
presentation efficiency as a basis for immunodominance [16].
These findings illustrate how numerous factors can intersect to
establish an immunodominance hierarchy and show that high
similarity to the host proteome hampers peptide immune
reactivity. Thus, removing host mimics from vaccine constructs
could be a crucial step toward designing not only safer but also
more efficacious HIV vaccines. Due to the lack of viral peptides
that are simultaneously similar to the host and strongly
immunogenic, we suggest design of HIV vaccine candidates using
non-self discrimination as a molding force in generating peptide
immunogenicity. Crafting more potent vaccine candidates hinges
upon the accurate understanding of the molecular mechanisms
involved in peptide immunogenicity, and particularly upon
a deeper insight into immunodominance.
MATERIALS AND METHODS
Database Searches and Sequence Analysis
Analyses of the degree of similarity between HIV-1 and the human
proteome were conducted using the HIV-1 subtype B consensus
sequence of 2001 available at the HIV immunology database
(http://www.hiv.lanl.gov/content/hiv-db/PEPTGEN/2001.html).
The 9 HIV-1 protein sequences were dissected into overlapping 4,
5, 6 or 9-mers offset by 1 residue, which were probed for sequence
similarity against a protein database representing the human
genome (27,606 proteins corresponding to 14,236,486 AA). The
non-redundant human protein collection was retrieved from the
RefSeq database, available at the NCBI website (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db=Protein). Searches against the
human library were run using ViroBLAST (Modification of the
Basic Local Alignment Search Tool available at: http://indra.
mullins.microbiol.washington.edu/)[29], with parameters set for
short, nearly exact match searches. The 4, 5 and 6-mers were
probed for exact matches with human protein sequences, while up
to 2 mismatches were allowed for 9-mers. Database hits were
curated manually based on sequence annotation and reference to
the literature; initial hits caused by contamination of the RefSeq
database bynon-human sequences (corresponding mostly to viralor
bacterial elements) were removed from further analyses. Similar
analyses were conducted for i) 182 Env protein sequences (C2-V5
region) dating from 1983 to 2005 and ii) 944 10-mer-sequences
spanning the Nef protein.
Immunological analysis
IFN-c ELISpot assays were performed using overlapping peptides,
as previously described [12]. They include 410 peptides (usually
18-mers–varying from 15 to 20 amino acids in length-overlapping
by 10 AA) spanning the entire HIV-1 subtype B consensus 2001
proteome, and were tested using PBMC from 314 HIV-1 infected
individuals. A set of 944 peptides (10-mers overlapping by 9 AA)
corresponding to HIV-1 subtype B Nef variants was tested using
PBMC from 30 HIV-1 infected individuals (Frahm et al, in
preparation). For each peptide, the numbers of matches found in
the similarity analyses (for all k-mers studied) were tallied and
compared to the peptide’s frequency of recognition in IFNc
ELISpot assays.
Multivariate analysis
Different parameters were analyzed for the 410 overlapping 18-
mer-peptides. The average Shannon entropy scores for all peptides
are available at the HIV immunology database (http://hiv-web.
lanl.gov/content/immunology/hlatem/study1/peptides.html).
The frequency of ‘‘forbidden’’ amino acids and cleavage scores
were determined for each peptide as described [12]. A disorder
score was calculated using predictions of order/disorder made
with the VSL1 predictor available at the PONDRH web-site
(http://www.pondr.com) [57]. The PONDRH Predictors of
Naturally Disordered Regions are feed-forward neural networks
that use primary sequence data (generally windows of 21 amino
acids). The predictions are smoothed over a sliding window of 9
amino acids: a residue is considered disordered if it exceeds
a threshold of 0.5. The composite predictor VSL1 was developed
to improve the prediction performance on short disordered regions
(,30 residues); the VSL1 implementation showed the best
prediction performance in an independent assessment of 20
order/disorder predictors [58]. Stepwise multiple-regression
analysis was carried out to model the contributions of these
variables to predicting the frequency of recognition for each
peptide.
Statistical analysis
Statistical analyses were done using JMPH version 5.1.2. Correla-
tions were considered statistically significant when p was ,0.05.
Randomization analysis of the frequency of recognition of HIV-
1 B consensus 2001 peptides as a function of their similarity to
human proteins. The values of the x axis (normalized similarity to
the human proteome) were randomized. The Null distribution
corresponds to the number of times when both x and y axes values
were greater than their means plus 1 standard deviation. 1000
randomizations were performed. The number of occurrences (with
both x and y axes values greater than their means plus 1 standard
deviation) were counted and compared to the observed number of
occurrences.
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